{"closest_prior_art":[{"name":"CONSORT-Outcomes 2022 Extension","overlap":"Requires complete outcome definitions, identification of prespecified and non-prespecified outcomes, disclosure of analyzed time points and exclusions, explanation of interim analyses, multiplicity-aware interpretation, reporting of all prespecified analyses, and exploratory labeling of unplanned analyses.","remaining_difference":"It is a reporting guideline, not a recovery-specific controlled workspace that inventories every executed analytic path, computes a hierarchical familywise and sequential-look status, maintains a claim-status passport, or conditions practice review on independent new-data replication.","source_ids":["SRC3"]},{"name":"Systematic Multiverse Analysis Registration Tool (SMART)","overlap":"Provides a structured first-party application for defining defensible analytic pipelines, planning multiplicity corrections, preregistering a multiverse, documenting decisions, and exporting a robustness record.","remaining_difference":"SMART documents planned multiverse construction but does not automatically capture every executed analysis, govern endpoint-family and interim-look error budgets, assign manuscript evidence statuses, or enforce independent replication before practice-facing eligibility.","source_ids":["SRC4"]},{"name":"FDA Multiple Endpoints in Clinical Trials Guidance","overlap":"Recognizes false-conclusion risk from multiple endpoints and describes grouping, ordering, and multiplicity-control strategies for study-level claims.","remaining_difference":"Its scope is regulated drug and biologic trials; it does not supply the proposed sport-recovery evidence passport, execution-history logging, multiverse summary, five-level claim-status scheme, or independent-replication eligibility rule.","source_ids":["SRC2"]}],"contrastive_claim_falsifier":"The contrast would be falsified by locating an established recovery-study workflow that already combines prospective endpoint and analysis-family registration, complete logging of executed alternatives and interim looks, hierarchical familywise and sequential-look control, multiverse reporting, explicit claim-status transitions, and a mandatory independent new-data replication gate before practice review. Operationally, it would also be weakened if the shadow replay cannot reconstruct the opportunity set reproducibly or produces no defensible status distinction beyond CONSORT, FDA, and SMART practices.","contrastive_claim_remaining":"Existing sources address multiplicity-aware endpoint reporting, hierarchical testing, preregistered multiverses, and replication separately. The remaining testable contrast is whether one recovery-specific passport can join the complete observed opportunity set to an auditable claim status and prevent a selected non-primary result from becoming practice-review eligible until an independently preregistered new-data replication succeeds.","experiment_id":"eoa_inverse_innovation_exp13_second_slot_policy60_20260806","gates":{"adequate_source_search":{"rationale":"The bounded search covered the proposal directly, p-hacking and multiverse terminology, reporting guidance and first-party tools, and combinations involving endpoints, time points, exclusions, interim looks, multiplicity, and replication. Exactly four opened sources from four publishers were retained, including primary research, official guidance, an official reporting standard, and a first-party product.","source_ids":["SRC1","SRC2","SRC3","SRC4"],"status":"PASS"},"bounded_next_test":{"rationale":"A shadow replay on one completed unpublished study is finite and measurable: reconstruct the opportunity set from existing records, apply the proposed rules, compare claim statuses, and have an independent methods reviewer judge reconstruction completeness. It requires no new participants, intervention changes, manuscript action, or practitioner communication.","source_ids":["SRC2","SRC3","SRC4"],"status":"PASS"},"distinct_testable_claim":{"rationale":"No retained source combines recovery-specific opportunity-set capture, execution logging, hierarchical familywise and sequential-look accounting, multiverse robustness, evidence-status transitions, and an independent new-data replication gate. Whether that integration changes claim status and is reconstructable is empirically testable.","source_ids":["SRC2","SRC3","SRC4"],"status":"PASS"},"no_obvious_safety_or_authority_stop":{"rationale":"The authorized first step uses existing authorized data in internal shadow mode, preserves PI and reviewer decision authority, excludes participant or manuscript changes, and specifies access-control, safety-delay, deletion, and rollback conditions. No obvious safety or authority stop is visible for that bounded replay.","source_ids":[],"status":"PASS"},"supported_problem":{"rationale":"Sport and exercise research shows materially limited replication and reporting-transparency barriers, while FDA and CONSORT sources directly recognize false-positive and selective-reporting risks from multiple outcomes, time points, analyses, exclusions, and interim examinations. Evidence is not specific enough to establish the alleged behavior in recovery studies, so support is partial rather than complete.","source_ids":["SRC1","SRC2","SRC3"],"status":"PASS"}},"prior_art_disposition":"ADJACENT_PRIOR_ART","problem_evidence":{"finding":"The general mechanism is visible: multiple endpoints and analytic opportunities can inflate false conclusions, and selective reporting across time points or unplanned analyses impairs appraisal. Sports and exercise science also has documented replication and transparency problems. The retained sources do not directly measure favorable-result selection in multi-endpoint recovery-method studies, so the domain-specific problem is only partly supported.","source_ids":["SRC1","SRC2","SRC3"],"status":"PARTLY_SUPPORTED"},"research_id":"eoa_inverse_innovation_exp13_light_screen_20260806","schema_version":1,"screen_id":"E13P069","screen_survival":true,"search_lanes":{"component_combination":{"no_result_note":"No retained result combined all proposed components into a recovery-specific evidence-status and replication-gating workflow.","queries":["FDA multiple endpoints hierarchical testing alpha spending guidance","exercise recovery studies multiple outcomes multiplicity selective reporting statistical analysis","\"multiverse analysis\" preregistration multiplicity replication evidence status"],"source_ids":["SRC2","SRC3","SRC4"]},"direct_problem_and_intervention":{"no_result_note":"The exact title and an integrated Recovery Study Evidence Passport were not located; this phrase miss is not treated as novelty evidence.","queries":["sport science multiple outcomes time points selective reporting p-hacking recovery studies","research evidence passport analysis provenance preregistration multiverse"],"source_ids":["SRC1","SRC3"]},"products_practices_and_standards":{"no_result_note":null,"queries":["official Registered Reports Center for Open Science preregistration replication exploratory confirmatory","first party software log every analysis executed computational reproducibility provenance multiverse analysis","research workflow evidence status exploratory confirmed replicated rejected tool"],"source_ids":["SRC2","SRC3","SRC4"]},"synonyms_and_historical_terms":{"no_result_note":null,"queries":["site:bjsm.bmj.com sports science selective reporting p-hacking multiple outcomes study","site:osf.io sport science questionable research practices survey multiple comparisons preregistration","sports science preregistration guidelines replication analysis transparency official"],"source_ids":["SRC1","SRC3","SRC4"]}},"sources":[{"claims_supported":["Only 7 of 25 preregistered replications in applied sports and exercise science met all stated robust-replication criteria.","Replication effect estimates substantially decreased, and investigators encountered poor data and reporting transparency."],"publisher":"Springer Nature / Sports Medicine","source_id":"SRC1","source_type":"PRIMARY_RESEARCH","title":"Estimating the Replicability of Sports and Exercise Science Research","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC12513899/"},{"claims_supported":["Increasing the number of analyzed endpoints raises false-conclusion risk without appropriate multiplicity adjustment.","Grouping and ordering endpoints and applying recognized multiplicity methods can control erroneous study-level conclusions."],"publisher":"U.S. Food and Drug Administration","source_id":"SRC2","source_type":"OFFICIAL_GUIDANCE","title":"Multiple Endpoints in Clinical Trials Guidance for Industry","url":"https://www.fda.gov/regulatory-information/search-fda-guidance-documents/multiple-endpoints-clinical-trials"},{"claims_supported":["Outcome multiplicity includes multiple outcomes, assessment time points, interim analyses, subgroups, and repeated analyses.","Trial reports should describe multiplicity methods, exclusions, stopping guidelines, all prespecified analyses, and non-prespecified exploratory analyses.","Multiple analyses create false-positive and selective-reporting risk."],"publisher":"American Medical Association / JAMA","source_id":"SRC3","source_type":"OFFICIAL_STANDARD","title":"Guidelines for Reporting Outcomes in Trial Reports: The CONSORT-Outcomes 2022 Extension","url":"https://jamanetwork.com/journals/jama/fullarticle/2799401"},{"claims_supported":["SMART is a working first-party application for systematically defining and documenting defensible multiverse pipelines.","It supports preregistration exports, analytic-decision documentation, multiplicity-correction planning, and robustness summaries.","The application does not determine which decisions are defensible and is not an evidence-status or replication-gating system."],"publisher":"META-REP / Ludwig Maximilian University of Munich","source_id":"SRC4","source_type":"FIRST_PARTY_PRODUCT","title":"Systematic Multiverse Analysis Registration Tool","url":"https://www.apps.meta-rep.lmu.de/SMART/"}],"world_novelty_boundary":"This was a coarse, bounded public-web screen, not an exhaustive literature, patent, product, or standards review. ADJACENT_PRIOR_ART means no close integrated match was retained in these searches; it does not establish world novelty, patentability, market size, expert acceptance, implementation feasibility, or realized scientific or practitioner value."}